ES2619322T3 - Agente inductor de inmunidad - Google Patents

Agente inductor de inmunidad Download PDF

Info

Publication number
ES2619322T3
ES2619322T3 ES14185710.2T ES14185710T ES2619322T3 ES 2619322 T3 ES2619322 T3 ES 2619322T3 ES 14185710 T ES14185710 T ES 14185710T ES 2619322 T3 ES2619322 T3 ES 2619322T3
Authority
ES
Spain
Prior art keywords
polypeptide
immunity inducing
agent
inducing agent
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14185710.2T
Other languages
English (en)
Spanish (es)
Inventor
Fumiyoshi Okano
Masaki Shimizu
Takanori Saito
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Toray Industries Inc
Original Assignee
Toray Industries Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries Inc filed Critical Toray Industries Inc
Application granted granted Critical
Publication of ES2619322T3 publication Critical patent/ES2619322T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ES14185710.2T 2008-08-05 2009-08-05 Agente inductor de inmunidad Active ES2619322T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008202065 2008-08-05
JP2008202065 2008-08-05

Publications (1)

Publication Number Publication Date
ES2619322T3 true ES2619322T3 (es) 2017-06-26

Family

ID=41663742

Family Applications (2)

Application Number Title Priority Date Filing Date
ES14185710.2T Active ES2619322T3 (es) 2008-08-05 2009-08-05 Agente inductor de inmunidad
ES09805008.1T Active ES2539603T3 (es) 2008-08-05 2009-08-05 Agente inductor de inmunidad

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES09805008.1T Active ES2539603T3 (es) 2008-08-05 2009-08-05 Agente inductor de inmunidad

Country Status (16)

Country Link
US (2) US8454968B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (2) EP2837383B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (2) JP5691171B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (3) KR102009241B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (2) CN103751771B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (2) AU2009278385B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (2) BR122020027042B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2732283C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (2) DK2837383T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (2) ES2619322T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HUE031343T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (2) MX348464B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (2) PL2837383T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (2) PT2324842E (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (2) RU2511039C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2010016525A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2322221B1 (en) 2008-08-05 2014-07-09 Toray Industries, Inc. Pharmaceutical composition for treatment and prevention of cancer
KR20160039295A (ko) 2008-08-05 2016-04-08 도레이 카부시키가이샤 암의 검출 방법
CN102822199B (zh) * 2010-02-04 2014-10-15 东丽株式会社 癌的治疗和/或预防用药物组合物
EP2532367B1 (en) * 2010-02-04 2018-08-29 Toray Industries, Inc. Pharmaceutical agent for treatment and/or prevention of cancer
CA2788718C (en) 2010-02-04 2019-05-21 Shinichi Kobayashi Caprin-1 antibody for treating and/or preventing cancer
PT2532366T (pt) * 2010-02-04 2016-12-20 Toray Industries Composição farmacêutica para o tratamento e/ou prevenção de cancro
CN102834113B (zh) 2010-02-04 2016-03-02 东丽株式会社 癌的治疗和/或预防用药物组合物
PL2532365T3 (pl) * 2010-02-04 2016-12-30 Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi
BR112013029704A2 (pt) * 2011-05-19 2017-08-29 Toray Industries Agente de indutor de imunidade e uso de um agente indutor de imunidade
CN103717737B (zh) * 2011-08-04 2015-06-10 东丽株式会社 癌的治疗和/或预防用药物组合物
BR112014002619A2 (pt) 2011-08-04 2018-10-09 Toray Industries, Inc composição farmacêutica e método de tratamento e/ou prevenção de câncer pancreático e combinação farmacêutica
AU2012290954B2 (en) * 2011-08-04 2017-08-31 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prophylaxis of cancer
US9796775B2 (en) 2011-08-04 2017-10-24 Toray Industries, Inc. Method for detecting pancreatic cancer
AU2012290957B2 (en) 2011-08-04 2017-04-20 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prophylaxis of cancer
RU2611197C2 (ru) * 2011-08-04 2017-02-21 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли
PT2740793T (pt) * 2011-08-04 2018-02-23 Toray Industries Composição de fármacos para o tratamento e/ou a prevenção de cancro
DK2824114T3 (da) 2012-02-21 2019-07-29 Toray Industries Farmaceutisk sammensætning til behandling af cancer
KR102005786B1 (ko) 2012-02-21 2019-07-31 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
CA2864999C (en) 2012-02-21 2020-06-30 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
EP2818482B1 (en) 2012-02-21 2019-05-22 Toray Industries, Inc. Pharmaceutical composition for treatment of cancer
JP6107655B2 (ja) * 2012-03-30 2017-04-05 東レ株式会社 胆嚢癌の治療及び／又は予防用医薬組成物
HUE036424T2 (hu) 2012-03-30 2018-07-30 Toray Industries Gyógyászati készítmény májrák kezelésére és/vagy megelõzésére
AU2013291047B2 (en) 2012-07-19 2018-12-06 Toray Industries, Inc. Cancer detection method
DK2876447T3 (da) 2012-07-19 2020-02-24 Toray Industries Fremgangsmåde til detektering af cancer
US9862774B2 (en) 2013-08-09 2018-01-09 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
RU2744843C2 (ru) * 2015-04-30 2021-03-16 Торэй Индастриз, Инк. Иммуноиндуцирующее средство
EP3533466A4 (en) * 2016-10-28 2020-06-10 Toray Industries, Inc. PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT AND / OR PREVENTION
KR20200136935A (ko) * 2018-03-30 2020-12-08 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
CN109206501B (zh) * 2018-09-26 2022-03-04 东北农业大学 猫干扰素ω、其编码基因及其在抗病毒方面的应用
CN109206502B (zh) * 2018-09-26 2022-03-04 东北农业大学 一种猫干扰素ω及其制备方法和在抗病毒中的应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US5698396A (en) 1995-06-07 1997-12-16 Ludwig Institute For Cancer Research Method for identifying auto-immunoreactive substances from a subject
WO2000004149A2 (en) * 1998-07-14 2000-01-27 Corixa Corporation Compositions and methods for therapy and diagnosis of prostate cancer
WO2002083070A2 (en) * 2001-04-10 2002-10-24 Corixa Corporation Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
US20030190640A1 (en) * 2001-05-31 2003-10-09 Mary Faris Genes expressed in prostate cancer
JP4533626B2 (ja) * 2001-11-07 2010-09-01 サイトス バイオテクノロジー アーゲー アレルギー性好酸球性疾患を治療するための抗原アレイ
US20050003390A1 (en) * 2002-05-17 2005-01-06 Axenovich Sergey A. Targets for controlling cellular growth and for diagnostic methods
US20060121029A1 (en) 2002-08-30 2006-06-08 Hiroshi Shiku Method and composition for regulating the activity of regulatory t cells
WO2005100998A2 (en) * 2004-04-16 2005-10-27 Europroteome Ag Membrane markers for use in cancer diagnosis and therapy
DE102004026135A1 (de) 2004-05-25 2006-01-05 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide
US8211634B2 (en) 2006-02-14 2012-07-03 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
US20080107668A1 (en) * 2006-08-30 2008-05-08 Immunotope, Inc. Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
KR20080075722A (ko) 2007-02-13 2008-08-19 엘지이노텍 주식회사 튜너
JP4826496B2 (ja) 2007-02-16 2011-11-30 三菱マテリアル株式会社 電解メッキ用アノード電極取付構造
WO2013143026A1 (en) * 2012-03-31 2013-10-03 Abmart (Shanghai) Co., Ltd Peptide and antibody libraries and uses thereof
US20140357512A1 (en) * 2013-06-03 2014-12-04 Acetylon Pharmaceuticals, Inc. Histone deacetylase (hdac) biomarkers in multiple myeloma

Also Published As

Publication number Publication date
AU2015210461A1 (en) 2015-09-03
AU2009278385A1 (en) 2010-02-11
MX2011001113A (es) 2011-03-04
KR20110044854A (ko) 2011-05-02
BRPI0912462B1 (pt) 2022-03-22
CN102112146A (zh) 2011-06-29
JP5962739B2 (ja) 2016-08-03
KR101669827B1 (ko) 2016-10-27
KR20160127146A (ko) 2016-11-02
US8454968B2 (en) 2013-06-04
KR102009241B1 (ko) 2019-08-09
PL2324842T3 (pl) 2015-08-31
BRPI0912462A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2016-02-02
HUE031343T2 (hu) 2017-07-28
MX339277B (es) 2016-05-19
JPWO2010016525A1 (ja) 2012-01-26
CN103751771A (zh) 2014-04-30
EP2324842A1 (en) 2011-05-25
BR122020027042B1 (pt) 2022-11-08
JP5691171B2 (ja) 2015-04-01
AU2009278385B2 (en) 2015-06-11
WO2010016525A1 (ja) 2010-02-11
EP2837383B1 (en) 2016-12-14
US20130230488A1 (en) 2013-09-05
ES2539603T3 (es) 2015-07-02
US9592281B2 (en) 2017-03-14
EP2324842B1 (en) 2015-03-25
US20110123492A1 (en) 2011-05-26
RU2639518C2 (ru) 2017-12-21
RU2013156620A (ru) 2015-06-27
RU2011108315A (ru) 2012-09-10
DK2837383T3 (en) 2017-03-20
AU2015210461B2 (en) 2017-07-13
PT2837383T (pt) 2017-03-17
CN102112146B (zh) 2014-03-12
EP2837383A1 (en) 2015-02-18
MX348464B (es) 2017-06-14
EP2324842A4 (en) 2012-05-23
CA2732283A1 (en) 2010-02-11
CN103751771B (zh) 2017-09-08
DK2324842T3 (da) 2015-06-22
KR20170128637A (ko) 2017-11-22
PT2324842E (pt) 2015-07-21
CA2732283C (en) 2017-12-05
PL2837383T3 (pl) 2017-07-31
RU2511039C2 (ru) 2014-04-10
JP2015061847A (ja) 2015-04-02

Similar Documents

Publication Publication Date Title
ES2619322T3 (es) Agente inductor de inmunidad
ES2512141T3 (es) Análogo peptídico de oxintomodulina
ES2652643T3 (es) Péptidos terapéuticos y su uso contra la corea de Huntington
MX2017013122A (es) Metodos de reparacion y regeneracion tisular.
AR080658A1 (es) Toxinas insecticidas cry dig-5 de bacillus thuringiensis
ES2691070T3 (es) Péptidos antiinflamatorios y composición que comprende los mismos
EA201500802A1 (ru) Способы профилактики и/или лечения кардиомиопатии и устранения симптомов кардиомиопатии, фармацевтическая композиция, векторы
AR067980A1 (es) Peptidos de cdh3 y agentes que los comprenden
CO2018012258A2 (es) Compuestos de mic-1 y usos de estos
AR114325A1 (es) Péptidos de la cadena b de la relaxina lipidados modificados y su uso terapéutico
ES2524251T3 (es) Proteínas de tipo interferón humano recombinantes
MX2021008131A (es) Metodos y composiciones para el tratamiento de la enfermedad de fabry.
GT201700224A (es) Proteína de unión a rgma y su uso
MX2022002056A (es) Compuestos para el tratamiento de enfermedad respiratoria bovina o porcina.
AR083126A1 (es) Composicion vacunal para el control de las infestaciones por ectoparasitos
AR114324A1 (es) Péptidos de la cadena b de la relaxina lipidados modificados y su uso terapéutico
ES2544954T3 (es) Péptidos multiméricos ramificados para diagnóstico y terapia de tumores
AR114323A1 (es) Péptidos de la cadena b de la relaxina modificados y su uso terapéutico
ES2609817T3 (es) Leucotoxina E/D como nuevo agente antiinflamatorio y microbicida
BR112014028130A2 (pt) Sal de cloridrato de um peptídeo, composição farmacêutica, uso de um sal de cloridrato, uso de uma composição farmacêutica, e, método para evitar ou tratar alergia a gatos
ES2534752T3 (es) Nuevo péptido antigénico contra el cáncer y utilización del mismo
MX392412B (es) Polipéptidos que tienen actividad inductora de inmunidad.
ES2605171T3 (es) Composiciones ansiolíticas que comprenden péptidos derivados de la Caseína ALFAs1
ES2633468T3 (es) Agente inductor de inmunidad y método para la detección del cáncer
ES2723098T3 (es) Agonistas del péptido CRHR2 y usos de los mismos